SCHEMBL24251059

SCHEMBL24251059

CCOC(=O)N1CCC(c2ccc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 11/20 0.61
PDGFRA P16234 10/20 0.61
ABL1 P00519 16/20 0.60
PDGFRB P09619 10/20 0.60
BCR P11274 10/20 0.60
EGFR P00533 2/20 0.59
PRKCA P17252 1/20 0.59
LYN P07948 2/20 0.59
PLK4 O00444 1/20 0.59
DDX3X O00571 1/20 0.59
GAK O14976 1/20 0.59
SLC22A2 O15244 1/20 0.59
MAPK13 O15264 1/20 0.59
CA12 O43570 1/20 0.59
SLC22A3 O75751 1/20 0.59
ABCB11 O95342 1/20 0.59
CA1 P00915 1/20 0.59
CA2 P00918 1/20 0.59
LMNA P02545 1/20 0.59
ALB P02768 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29551043 1.00 KIT (0.61) KITPDGFRAABL1PDGFRBBCR
SCHEMBL24251152 0.96 ABL1 (0.67) KITPDGFRAABL1PDGFRBBCR
SCHEMBL29551261 0.96 ABL1 (0.67) KITPDGFRAABL1PDGFRBBCR
SCHEMBL29551817 0.92 KIT (0.58) KITPDGFRAABL1PDGFRBBCR
SCHEMBL24251153 0.92 KIT (0.58) KITPDGFRAABL1PDGFRBBCR
SCHEMBL24251191 0.92 ABL1 (0.57) KITPDGFRAABL1PDGFRBBCR
SCHEMBL29551569 0.92 ABL1 (0.57) KITPDGFRAABL1PDGFRBBCR
SCHEMBL24251138 0.91 ABL1 (0.69) KITPDGFRAABL1PDGFRBBCR
SCHEMBL29551790 0.91 ABL1 (0.69) KITPDGFRAABL1PDGFRBBCR
SCHEMBL24251098 0.90 ABL1 (0.69) KITPDGFRAABL1PDGFRBBCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114127065-A Compounds for the treatment of neurodegenerative diseases and cancer 鸿仪有限责任公司 2022-03-01 CN claimed
US-20220048893-A1 Compounds for Treating Neurodegenerative Diseases and Cancers HONGYI & ASS LLC (US) 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048893-A1 Compounds for Treating Neurodegenerative Diseases and Cancers SNCA, NGF, SLC18A2 KIT 2333/4885PDGFRA 145/4885ABL1 695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.